Dihydroergotamine mesylate inhalation powder

Dihydroergotamine mesylate inhalation powder is a drug-device combination product being developed by Aspeya Switzerland SA for the acute treatment of migraine. It utilizes a proprietary dry powder inhaler (DPI) to deliver dihydroergotamine (DHE), an ergot alkaloid, directly to the lungs for rapid systemic absorption. DHE acts as a potent agonist at multiple serotonin receptors, specifically 5-HT1B, 5-HT1D, and 5-HT1F, which leads to the constriction of inflamed intracranial blood vessels and the inhibition of pro-inflammatory neuropeptide release from trigeminal nerve endings. This formulation is designed to provide the rapid onset of action typically associated with intravenous administration while offering the convenience and non-invasive nature of inhalation, potentially improving patient compliance and outcomes in acute migraine management.

Other names

DHE inhalation powderDHE dry powder inhalerDHE DPI